Combioxin signs a worldwide licensing agreement
Share this article
Combioxin has signed a worldwide licensing agreement with Eagle Pharmaceuticals
Eagle Pharmaceuticals has entered into a worldwide licensing agreement with Combioxin SA, a Swiss clinical-stage biotech company, for the commercial rights to CAL02, a novel first-in-class antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs. Eagle expects to invest $35 million and anticipates ten years of regulatory exclusivity.
Under the Agreement, Eagle Pharmaceuticals will be solely responsible for the further clinical development of Combioxin’s CAL02. They will make an upfront payment, followed by additional payments upon achievement of development milestones, regulatory approval and based upon commercial sales. Eagle expects to invest $35 million to achieve interim results, expected in the first half of 2023.